Date: 2015-02-04
Type of information: Nomination
Compound: chief executive officer
Company: Rigontec (Germany)
Therapeutic area: Cancer - Oncology - Infectious diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On February 4, 2015, Rigontec announced the appointment of Dr. Christian Schetter as CEO. Dr. Schetter joins Rigontec from Neovii Biotech GmbH, previously Fresenius Biotech , where he was President & CEO. During his tenure one antibody product was brought to market and the indication for another product expanded. Dr. Schetter was instrumental in selling Fresenius Biotech to the Neopharm Group to form Neovii Biotech and positioning it as a successful standalone business. Prior to joining Fresenius, Dr. Schetter was Senior Vice President, European Operations of Coley Pharmaceutical Group, Inc, a pioneer in the development of immunostimulatory oligonucleotides, and served as Managing Director of Coley GmbH. He was part of the leadership team which built Coley Pharmaceuticals from inception through multiple financing rounds, a NASDAQ IPO and, following a number of significant pharma deals, to a trade sale to Pfizer in 2007. Dr. Schetter joined Coley from the Max Planck Institute in Martinsried, Germany. He received his undergraduate degree and PhD from the University of Cologne and did postdoctoral research in oncology and virology at the Scripps Research Institute in La Jolla, California. He is a member of the Executive Board of BIO Deutschland, the German biotech business association.
Financial terms:
Latest news:
Is general: Yes
